Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Serotonin 5-HT1 receptor family is a group of five G protein-coupled receptors (5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F) that primarily signal through the inhibitory Gi/o pathway to decrease cyclic AMP levels [1, 6]. These receptors are widely distributed in the central nervous system, where they function as both presynaptic autoreceptors and postsynaptic heteroreceptors to modulate neuronal excitability and neurotransmitter release [1, 13, 18]. 5-HT1A receptors are key targets for anxiolytic and antidepressant drugs, while 5-HT1B, 5-HT1D, and 5-HT1F receptors are critical in the management of migraines through their effects on cranial blood vessels and trigeminal nerve signaling [1, 2, 5]. Dysregulation of this family is linked to various neuropsychiatric conditions, including major depressive disorder, generalized anxiety disorder, and schizophrenia [1, 12, 13]. Pharmacological modulation of these receptors is a cornerstone of modern neuropharmacology, though it requires careful management of side effects such as serotonin syndrome and potential cardiovascular risks associated with vasoconstriction [3, 4, 11]. While 5-HT1A, 1B, and 1D are well-characterized, 5-HT1E and 1F are increasingly recognized for their roles in neuroprotection and non-vasoconstrictive migraine relief, respectively [1, 6].
Activation of 5-HT1 receptors (agonism) triggers Gi/o protein signaling, which inhibits adenylyl cyclase activity and reduces intracellular cyclic AMP (cAMP) levels [1, 2, 6]. This signaling cascade typically leads to the opening of G protein-coupled inwardly rectifying potassium (GIRK) channels, causing neuronal hyperpolarization, and the inhibition of voltage-gated calcium channels, which reduces the release of neurotransmitters such as serotonin, glutamate, and acetylcholine [1, 13, 18]. In the vasculature, 5-HT1B/1D activation induces vasoconstriction of cranial blood vessels [1, 2, 5].
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serotonin 5-HT1 receptor family (5-HT1) (5-HT1).